Everest Medicines has dosed the first patient in a registrational China Phase IIb trial of Trodelvy TM to treat metastatic triple-negative breast cancer. Trodelvy (sacituzumab govitecan) is a first-in-class antibody-drug conjugate directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. Last year, Everest in-licensed Greater China rights to Trodelvy from Immunomedics in an agreement worth up to $835 million. Immunomedics recently released US Phase III data showing significantly improved PFS and OS results for Trodelvy. More details.... Stock Symbols: (HK:1952) (NSDQ: IMMU) Share this with colleagues: // //